Dose-dense adjuvant chemotherapy for primary breast cancer Journal Article
| Authors: | Fornier, M.; Norton, L. |
| Article Title: | Dose-dense adjuvant chemotherapy for primary breast cancer |
| Abstract: | Adjuvant chemotherapy has been proven to reduce significantly the risk for relapse and death in women with operable breast cancer. Nevertheless, the prognosis for patients presenting with extensive axillary lymph node involvement remains suboptimal. In an attempt to improve on the efficacy of existing chemotherapy, a phase III intergroup trial led by the Cancer and Leukemia Group B (CALGB 97-41) was designed, which tested a mathematical model of tumor growth based on the Norton-Simon hypothesis. This hypothesis, developed about 3 decades ago, and the kinetic model derived from it, created the basis of the concepts of dose density and sequential therapy, both of which were tested in CALGB 97-41. This large prospective randomized trial demonstrated that shortening the time interval between each chemotherapy cycle while maintaining the same dose size resulted in significant improvements in disease-free and overall survival in patients with node-positive breast carcinoma. This finding is highly relevant and has immediate implications for clinical practice. |
| Keywords: | doxorubicin; cyclophosphamide; epirubicin; women; high-risk; phase-ii; randomized-trial; regimen; feasibility; sequential paclitaxel |
| Journal Title: | Breast Cancer Research |
| Volume: | 7 |
| Issue: | 2 |
| ISSN: | 1465-5411 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2005-01-01 |
| Start Page: | 64 |
| End Page: | 69 |
| Language: | English |
| DOI: | 10.1186/bcr1007 |
| ACCESSION: | WOS:000227583300005 |
| PROVIDER: | wos |
| PMCID: | PMC1064124 |
| PUBMED: | 15743513 |
| Notes: | --- - Review - "Source: Wos" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work